Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2009
04/14/2009US7517998 Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus
04/14/2009US7517996 methyl 3-(4-{4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-isoxazolyl}-benzylsulfanyl)propionate; compounds inhibit the physiological activity of lysophosphatidic acid (LPA); treatment of fibrosis of organs (liver, kidney, lung, and the like), hepatic disease
04/14/2009US7517995 Thiazolyl-dihydro-cyclopentapyrazole
04/14/2009US7517994 Heterocyclic inhibitors of MEK and methods of use thereof
04/14/2009US7517993 Pioglitazone hydrochloride
04/14/2009US7517992 (-)-cis-1-(5-(4-fluorophenoxy)-pyridin-2-yl)-3-(4,7-difluoro-1,1a,2,7b-tetrahydro-cyclopropa[c]chromene-1-yl)-urea; improved resistance and pharmacokinetic profile; polymerase inhibitors; potent against virus comprising drug escape mutations
04/14/2009US7517991 metabolic and eating disorders, improvement of cognitive function, substance abuse disorders, cognitive disorders, autoimmune glomerulonephritis
04/14/2009US7517989 Piperidine derivatives useful as modulators of chemokine receptor activity
04/14/2009US7517988 N-hydroxy-4-[2-(benzofuran-2-ylcarbonylamino)ethylsulfonyl]-benzamide; hepatitis C; inhibitors of histone deacetylase
04/14/2009US7517987 Interleukin converting enzyme inhibitors such as 5-Fluoro-4-oxo-3-(2-(6-oxo-6H-pyrimidin-1-yl)-butyrylamino)-pentanoic acid, administered as modulators of cell apoptosis and inflammation
04/14/2009US7517980 drugs having a high receptivity for hemagglutinins, used for diagnosis and therapy of bacterial infections
04/14/2009US7517971 Muteins of human telomerase reverse transcriptase lacking telomerase catalytic activity
04/14/2009US7517962 TWEAK receptor
04/14/2009US7517953 With low peroxide and anisidine values and high polyunsaturated fatty acid content; heating from 40 to 70 degrees C at a rate of 1 degree per minute, a plateau stage, cooling at the same rate; improved electrical efficency; baby formula
04/14/2009US7517913 ribozyme ribonuclease P, interleukin-2 and interferon- gamma inhibitors; for neoplastic, keratinization and inflammatory disorders; N1,N12-Bisretinoylspermine; condensation of polyamines or suitably protected derivatives with vitamin A derivatives
04/14/2009US7517912 to stimulate hair growth, restore hair color to depigmented hair, alopecia; side effects reduction; 17-phenyl trinor PGF2 alpha cyclopropyl methyl amide
04/14/2009US7517911 3,4,5-trimethoxy phenyl-based ester compound and preparation method thereof and whitening cosmetic composition containing the same
04/14/2009US7517910 Alkoxyphenylpropanoic acid derivatives
04/14/2009US7517909 Using 3-amino-5-methyl-octanoic acid for therapy of psychiatric, pain and other disorders
04/14/2009US7517908 Administering serotonin enhancer (e.g., a serotonin reuptake inhibitor) and concurrently administering 5-hydroxytryptophan to enhance the activity of the serotonin enahancer for therapy of unipolar major depression
04/14/2009US7517907 specific activator of retinoic acid receptors subtype beta; 6-[3-adamantan-1-yl-4-(2,2-dimethyl[1,3]dioxoian-4-ylmethoxy)phenyl]naphthalene-2-carboxylic acid; useful in human or veterinary medicine; for body/hair hygiene, treating acne-prone skin, promoting hair regrowth, limiting hair loss, dry skin
04/14/2009US7517906 Dimeric IAP inhibitors
04/14/2009US7517905 highly potent; side effect reduction; for the treatment of diseases of the respiratory, urinary and gastrointestinal systems; 3-(2-Methoxy-5-methylphenyl)-3-phenylpropionic acid-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-carbamoyl)methyl ester; condensation; deprotection
04/14/2009US7517904 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
04/14/2009US7517903 1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indole-4-one (CBI) with incorporated alkylating domain; in vivo drug-cleavable substrate conjugates that are potent cytotoxins; antiproliferative, anticarcinogenic agent; leukemia; bone marrow and mucosal toxicity; chronic cardiac and neurological toxicity
04/14/2009US7517902 1-[4-(3-amino-7-fluoro-1H-indazol-6-yl)phenyl]-3-(2-fluoro-5-trifluoromethyl-phenyl)urea; protein kinases (Vascular Endothelial Growth Factor Receptor 2 and Tie-2), inhibitor; anticarcinogenic, antiinflammatory agent; neovascularization, lung and breast cancer, rheumatoid arthritis
04/14/2009US7517901 p38 MAP kinase inhibitors and methods for using the same
04/14/2009US7517900 Pyrazole derivatives as cannabinoid receptor modulators
04/14/2009US7517899 Phenylaminopropanol derivatives and methods of their use
04/14/2009US7517898 2-tert-Butyl-N,N-diethyl-1-{[1-methylpiperidin-2-yl]methyl}-1H-benzimidazole-5-carboxamide; cannabinoid receptors agonists; analgesic, anticarcinogenic, antiinflammatory, anxiolytic agent; neurodegenerative diseases; gastrointestinal and cardiovascular disorders
04/14/2009US7517896 e.g. methyl 4-{[(5-ethoxy-5-oxopentyl)(2-methoxyphenethyl)amino]methyl}benzoate; stimulant of guanylate cyclase; catalyse the biosynthesis of cGMP from guanosine triphosphate (GTP); cardiovascular disorders; liver fibrosis
04/14/2009US7517895 Synthetic diazonamides
04/14/2009US7517894 Endothelial growth factor; angiogenesis inhibitor; antitumor agents; skin disorders; endometriosis; Crohn's disease; leukemia; antiarthritic agents
04/14/2009US7517893 Bichalcophenes and their prodrugs as antiprotozoal agents
04/14/2009US7517892 Ligands for monoamine receptors and transporters, and methods of use thereof
04/14/2009US7517891 7-[4'S,5'R-4',6'-di-O-acetyl-2',3'-dideoxy-D-erythro-hex-2'-enopyranosyl]-oxymethyl camptothecin 20-(4-bromo)-n-butyrate; breast cancers, ovarian cancer, colon cancer, malignant melanoma, small cell lung cancer, thyroid cancers, lymphomas, leukemias, AIDS
04/14/2009US7517890 e.g. N6-(2-((4-(diethylamino)-1-methylbutyl)amino)-6-methyl-4-pyrimidinyl)-2-methyl-4,6-quinolinediamine; guanosine triphosphatease Rac inhibitor; with other active drug, s.a. farnesyl-, prenyl-, geranylgeranyl- protein transferase inhibitors
04/14/2009US7517889 2-(3-{6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid; allergic disease; systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch
04/14/2009US7517888 A1 adenosine receptor antagonists
04/14/2009US7517887 Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
04/14/2009US7517886 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
04/14/2009US7517885 e.g. 1-{c-4-[4-(2-isopropoxy-phenyl)-piperazin-1-yl]-; 467; 2.900;cyclohexyl}-r-3-(2-methoxy-phenyl)-urea; selective alpha 1a/ alpha 1d adrenoreceptor modulators; benign prostatic hypertrophy and lower urinary tract symptoms
04/14/2009US7517884 {5-[4-(4-Trifluoromethyl-phenyl)-piperazine-1-sulfonyl]-indan-2-yl}-acetic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury, diabetes
04/14/2009US7517883 Solubilized topoisomerase poisons
04/14/2009US7517882 Protein kinase inhibitors
04/14/2009US7517881 Triazine derivatives, their preparation and therapeutic application thereof
04/14/2009US7517880 Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
04/14/2009US7517879 Pyrrolidine derivatives as factor Xa inhibitors
04/14/2009US7517878 For example, 2-([3-tert-butyl-1-(2-methylphenyl)-1H-pyrazol-5-yl]amino)-6-methylnicotinic acid; compounds stimulate insulin secretion in the presence of glucose
04/14/2009US7517876 e.g. N-[3-(4-butyl-1,4-dihydroxy-3-oxo-3,4-dihydronaphthalen-2-yl)-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide; viricide; hepatitis C (HCV) polymerase inhibitor; hepatitis , cirrhosis, end-stage liver disease, and liver cancer; side effect reduction
04/14/2009US7517875 Piperidine derivatives having CCR3 antagonism
04/14/2009US7517874 Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of pain
04/14/2009US7517873 Polo-like kinase inhibitor, antitumor agent, antiproliferative agent for treating breast, colon, lung and prostate tumors; 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-benzoic acid; chemical intermediates
04/14/2009US7517872 Enzyme inhibitors; interferons; interleukins; cyclosporins; Cycloprop[d]indolo[2,1-a][2]benzazepine/indolo[2,1-a][2]benzazepine derivatives; N'-(5-((sec-Butylsulfonyl)carbamoyl)-8-cyclohexyl-11-methoxy-1,12b-dihydrocyclopropa[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl)-N,N-dimethylethanediamide
04/14/2009US7517871 Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
04/14/2009US7517869 Atherosclerosis; ethyl (E)-2-(4-hydroxy-3-methoxyphenyl)vinyl-phosphonofluoridoate; fluorination of organophosphorus compounds, including organothiophosphorus compounds, to form corresponding fluoro(thio)phosphorus compounds
04/14/2009US7517868 Phytic citrate compounds and process for preparing the same
04/14/2009US7517867 Topoisomerase inhibitors; useful as antibacterial, antifungal agents; cancer; structure is based on substituted benzo(i)phenanthridine ring where the ring carbon atoms at position 5 and 11 are optionally replaced by nitrogen
04/14/2009US7517866 LIM mineralization protein splice variants
04/14/2009US7517862 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
04/14/2009US7517861 Containing unmethylated CpG dinucleotides; redirection of a Th2 response to a Th1 response; atopic diseases, dermatitis
04/14/2009US7517859 Spirocyclic bicyclolides
04/14/2009US7517858 Prodrugs of pharmaceuticals with improved bioavailability
04/14/2009US7517851 Carbohydrate containing mannose; prevent binding of chlamydia to mammal cells
04/14/2009US7517683 Gene expression of alphavirus; nucleotide sequences; induce immunology response; aids vaccine
04/14/2009US7517672 Nucleic acids encoding mammalian T-type calcium channels
04/14/2009US7517669 Increasing the intracellular amount of at least one ferritin-H or a derivative to an effective level for suppressing disease caused or enhanced by effects of intracellular iron mismanagement
04/14/2009US7517658 Drug screening for human SNORF33 receptor agonist by contacting cells transfected with and expressing DNA encoding the human SNORF33 receptor, wherein cells prior to being transfected with the DNA do not express the human SNORF33 receptor; inflammation, infections, arthritis; autoimmune diseases
04/14/2009US7517646 Provides functional molecule having an affinity and specificity to a target comparable to the affinity and specificity of an antibody against an antigen; modified oligonucleotide sequence
04/14/2009US7517644 Administering an expression vector, a double stranded oligodeoxynucleotide, or an antisense oligodeoxynucleotide to treat cancer, AIDS or other Aberrant Programming Disease; regulating expression of a transcriptional regulator; antiapoptosis
04/14/2009US7517540 Cranberry seed oil extract and compositions containing components thereof
04/14/2009US7517535 Agonists and antagonists of nicotinergic acetylcholine receptors of insects like fleas, lice and flies, on humans or animals; chloronicotinyl insecticides such as imidaclopridas veterinary medicine; collars; tags
04/14/2009US7517532 Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
04/14/2009US7517531 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
04/14/2009US7517526 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
04/14/2009US7517525 Methods of inhibiting amyloid toxicity
04/14/2009US7517519 Topical immune disorders of the scalp, and scalp conditions; immunosuppressant selected from the group consisting of tacrolimus, cyclosporin and carrier therefor, as a mousse, foamable on dispensing
04/14/2009US7517517 Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
04/14/2009CA2595907C Creatine hydroxycitric acid salts and methods for their production and use in individuals
04/14/2009CA2530474C Remedy for sarcoidosis and method of treating the same
04/14/2009CA2468658C [1,2,4]-triazole bicyclic adenosine a2a receptor antagonists
04/14/2009CA2445506C Use of sucralfate for the treatment of cervical erosion
04/14/2009CA2427817C Estrone-derivatives having cytoprotective activity
04/14/2009CA2424088C Skin preparation
04/14/2009CA2417050C Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
04/14/2009CA2412213C A method for treating septic shock
04/14/2009CA2409841C Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
04/14/2009CA2408934C Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
04/14/2009CA2396865C Farnesyl protein transferase inhibitors for treating breast cancer
04/14/2009CA2395016C Treatment of dna viral infections
04/14/2009CA2389111C Novel combination of loteprednol and .beta.2-adrenoceptor agonists
04/14/2009CA2387844C Treatment of emphysema using rar selective retinoid antagonists
04/14/2009CA2387532C Suppressor of anemia and appetite suppressor
04/14/2009CA2386190C Regulators of the hedgehog pathway, compositions and uses related thereto
04/14/2009CA2385863C New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds
04/14/2009CA2380980C Mutilin derivatives and their use as antibacterials
04/14/2009CA2371789C Novel guanidine derivatives as inhibitors of cell adhesion
04/14/2009CA2362914C Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
04/14/2009CA2359440C Phenylphenanthridines with pde-iv inhibiting activity
04/14/2009CA2355341C The use of ara as a supplement for a lactating woman